Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients

References

• Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907.
   PubMed Web of Science ®Google Scholar
• Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019;56(2):84–89.
   PubMed Web of Science ®Google Scholar
• Shafat MS, Gnaneswaran B, Bowles KM. Rushworth SA: the bone marrow microenvironment - home of the leukemic blasts. Blood Rev. 2017;31(5):277–286.
   PubMed Web of Science ®Google Scholar
• Lamble AJ, Lind EF. Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity. Front Oncol. 2018;8:213.
   PubMed Web of Science ®Google Scholar
• Ismail MM, Abdulateef NAB. Bone marrow T-cell percentage: a novel prognostic indicator in acute myeloid leukemia. Int J Hematol. 2017;105(4):453–464.
   PubMed Web of Science ®Google Scholar
• Lamble AJ, Kosaka Y, Laderas T, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2020;117(25):14331–14341.
   Google Scholar
• Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118(19):5084–5095.
   PubMed Web of Science ®Google Scholar
• Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8(2):191–197.
   PubMed Web of Science ®Google Scholar
• Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007;319(1–2):41–52.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Hess AD, Gocke CD, et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2011;117(2):608–617.
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res: An Official Journal Am Assoc Cancer Res. 2009;15(10):3325–3332.
   PubMed Web of Science ®Google Scholar
• Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129(6):1373–1381.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;114(18):3793–3802.
   PubMed Web of Science ®Google Scholar
• Xu Y, Mou J, Wang Y, et al. Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway. Leukemia. 2022;36(2):403–415.
   Google Scholar
• Mizui M, Koga T, Lieberman LA, et al. Tsokos GC: IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunol. 2014;193(5):2168–2177.
   PubMed Web of Science ®Google Scholar
• Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371–381.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Isidori A, Salvestrini V, Ciciarello M, et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol. 2014;7(6):807–818.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou Y, Chen P, et al. Excessive expressions of T cell activation markers in pediatric immune thrombocytopenia. Thromb Res. 2019;180:1–9.
   PubMed Web of Science ®Google Scholar
• Klion AD, Law MA, Riemenschneider W, et al. Familial eosinophilia: a benign disorder? Blood. 2004;103(11):4050–4055.
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Stamatopoulos K, Damianaki A, et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. Br J Haematol. 2005;128(6):863–876.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhu X, Zhang T, et al. EBV-HLH children with reductions in CD4+ T cells and excessive activation of CD8+ T cells. Pediatr Res. 2017;82(6):952–957.
   PubMed Web of Science ®Google Scholar
• Reddy M, Eirikis E, Davis C, et al. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004;293(1–2):127–142.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Chaturvedi V, Marsh RA, Zoref-Lorenz A, et al. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021;137(17):2337–2346.
   PubMed Web of Science ®Google Scholar
• Van den Hove LE, Vandenberghe P, Van Gool SW, et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res. 1998;22(2):175–184.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Y, Johnson A, et al. Combined CD25, CD64, and CD69 biomarker panel for flow cytometry diagnosis of sepsis. Talanta. 2019;191:216–221.
   PubMed Web of Science ®Google Scholar
• Miki-Hosokawa T, Hasegawa A, Iwamura C, et al. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol. 2009;183(12):8203–8215.
   PubMed Web of Science ®Google Scholar
• Zhigarev D, Varshavsky A, MacFarlane A, et al. Lymphocyte exhaustion in AML patients and impacts of HMA/venetoclax or intensive chemotherapy on their biology. Cancers. 2022;14(14):3352.
   PubMed Web of Science ®Google Scholar
• St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30(9):695–704.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu L, Yao D, et al. PD-1 and TIGIT Are highly Co-expressed on CD8(+) T cells in AML patient bone marrow. Front Oncol. 2021;11:686156.
   PubMed Web of Science ®Google Scholar
• Brauneck F, Haag F, Woost R, et al. Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML. Oncoimmunology. 2021;10(1):1930391.
   PubMed Web of Science ®Google Scholar
• Le Dieu R, Taussig DC, Ramsay AG, et al. Gribben JG: peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114(18):3909–3916.
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 2019;110(7):2080–2089.
   Google Scholar
• Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. 2019;125(9):1470–1481.
   Google Scholar
• Jia B, Wang L, Claxton DF, et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J. 2018;8(3):34.
   PubMedGoogle Scholar
• Pyzer AR, Stroopinsky D, Rajabi H, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129(13):1791–1801.
   PubMed Web of Science ®Google Scholar
• Knaus HA, Berglund S, Hackl H, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018;3(21):e120974.
   PubMed Web of Science ®Google Scholar